

David S. Mathai, MD

2121 Biscayne Blvd #1255 • Miami, FL 33137
E-MAIL D.S.MATHAI@GMAIL.COM

CURRENT EMPLOYMENT

Sattva Medicine, PLLC

July 2023 – present

- Private practice owner and psychiatrist based in Miami, Florida
- Clinical role includes prescribing, directing or administering psychotherapeutic treatment and/or medication to treat psychiatric conditions, gathering and maintaining patient information and records including social and medical histories, designing individualized care plans using a variety of treatments, collaborating with other healthcare professionals to discuss treatment plans and progress, analyzing and evaluating patient data or test findings to diagnoses nature or extent of illness

The Johns Hopkins University School of Medicine, Baltimore, MD

July 2023 – present

- Volunteer Assistant Professor with the Johns Hopkins Department of Psychiatry and Behavioral Sciences
- Research faculty for studies involving therapeutic use of psychedelic interventions

RECENT EMPLOYMENT

Segal Trials

September 2023 – January 2024

- Physician sub-investigator for Phase 1 – 3 schizophrenia and depression drug development trials at privately held inpatient research site based in Miami Lakes, Florida
- Role involved performing study procedures and related duties in compliance with IRB-approved protocols including: informed consent, patient screening and assessment of inclusion/exclusion criteria per study protocols, reviewing medical and psychiatric histories, performing daily rounds and clinical/research assessments, performing therapeutic procedures, adverse event/serious adverse event assessment and reporting, medical management of adverse events, physical examinations, evaluation of laboratory reports and ECGs, prescribing psychotropic medications, applying safety principles as identified by relevant policies, source documentation, ensuring compliance with legal issues (including but not limited to patient confidentiality and risk management according to JCAHO, federal, state, and local regulations), sponsor communication, coverage for primary investigator, and participation in continuing education
- Delegated to and involved with the following studies:
 - CVL231-2002 (*Cerevel Therapeutics*): Phase 2 RCT to evaluate the efficacy, safety, and tolerability of emraclidine (selective M4 positive allosteric modulator) in adults with schizophrenia experiencing an acute exacerbation of psychosis
 - CVL231-2003 (*Cerevel Therapeutics*): Phase 2 open-label trial to evaluate the long-term safety and tolerability of emraclidine in adults with schizophrenia
 - TV44749-CNS-30096 (*Teva Pharmaceuticals*): Phase 3 RCT to evaluate the efficacy, safety, and tolerability of subcutaneous olanzapine extended-release injectable suspension in adults with schizophrenia experiencing an acute exacerbation of psychosis
 - NBI-1117568-SCZ2028 (*Neurocrine Biosciences*): Phase 2 RCT to evaluate the efficacy, safety, tolerability, and pharmacokinetics of NBI-1117568 (selective M4 agonist) in adults with schizophrenia experiencing an acute exacerbation of psychosis
 - SEP361-121 (*Sunovion Pharmaceuticals*): Phase 1 RCT to evaluate if ulotarant (TAAR1 + 5-HT1A agonist) has physical dependence in adults with schizophrenia
 - LB-102-003 (*LB Pharmaceuticals*): Phase 2 RCT to evaluate the efficacy and safety of LB-102 (N-methylated analog of amisulpride) in adults with schizophrenia experiencing an acute exacerbation of psychosis
 - SUVN-911 (*Suven Life Sciences*): Phase 2 open-label study to evaluate the safety and efficacy of ropanicant ($\alpha 4\beta 2$ nicotinic acetylcholine receptor antagonist) in adults with moderate to severe major depressive disorder

Teladoc Health Medical Group, PA

June 2023 – November 2023

- Telehealth contract psychiatrist for telemedicine and virtual healthcare company based in Lewesville, Texas
- Role involved assessment and care for patients with a broad range of psychiatric diagnoses

The Johns Hopkins University School of Medicine, Baltimore, MD

July 2021 – June 2023

- Assistant faculty psychiatrist with Addiction Treatment Services (ATS) and the Center for Addiction and Pregnancy (CAP) with the Department of Psychiatry and Behavioral Sciences
- Postdoctoral research fellow with the Center for Psychedelic and Consciousness Research; roles included scientific collaborator, study physician, and session therapist for medication-assisted interventions
- Delegated to and involved with the following studies:
 - #NA_00016166: Psilocybin-facilitated smoking cessation treatment: A pilot study
 - #IRB00281685: Effects of psilocybin in post-treatment Lyme Disease Syndrome
 - #IRB00175915: Pilot study of 5-HT2A agonist psilocybin for depression in patients with mild cognitive impairment or early Alzheimer's Disease
 - #IRB00217137: A prospective online study of naturalistic psilocybin use
 - #IRB00304584: Examining the relationship between esketamine-induced dissociation and antidepressant effects
 - #IRB00326708: Pilot study of augmented esketamine therapy for treatment-resistant depression
 - #IRB00326708: Anonymous online survey of psychedelic attitudes in healthcare professionals
 - #IRB0233684: Psilocybin treatment for major depression disorder with co-occurring alcohol use disorder

The Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX July 2017 – June 2021

- Baylor College of Medicine Psychiatry Research Track Resident
- Clinical role involved assessment and care for patients with a broad range of psychiatric diagnoses; research role defined elsewhere

LICENSURE & CERTIFICATIONS

2020	Certified in Ketamine-Assisted Psychotherapy Training by Polaris Insight Center
2021	Certified in Psychiatry by the American Board of Psychiatry and Neurology
2021	Controlled Substance Registration by the Drug Enforcement Administration
2021	Maryland State Medical License (#D0091456)
2022	Certified in MDMA Therapy Training by the Multidisciplinary Association for Psychedelic Studies (MAPS)
2023	Florida State Medical License (#ME161728)

EDUCATION & TRAINING

Texas Academy of Mathematics and Science, Denton, TX August 2007 – May 2009

- Graduated with Honors Distinction

Texas A&M University, College Station, TX August 2009 – December 2012

- Bachelor of Science, Biochemistry and Genetics with English minor, Magna Cum Laude
- University Honors & Honors Fellows Distinctions; Thesis: "S100 inhibitors: A new paradigm for treating Alzheimer's Disease."

Baylor College of Medicine, Houston, TX July 2013 – May 2017

- Doctor of Medicine with Hilde Bruch Award for Excellence in Psychiatry

The Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX July 2017 – June 2021

- Baylor College of Medicine Psychiatry Research Track Resident
- Research supervisors: Sanjay Mathew, MD, Christopher Verrico, PhD, Eric Storch, PhD, and and Thomas Kosten, MD
- Psychotherapy supervisors: Kriste Babbitt, MD, Daniel Brener, MD, James Lomax, MD, and Glen Gabbard, MD

The Johns Hopkins University School of Medicine, Baltimore, MD July 2021 – June 2023

- Postdoctoral research fellowship with the Center for Psychedelic and Consciousness Research
- Research supervisors: Roland Griffiths, PhD and Albert Garcia-Romeu, PhD

RESEARCH

University of North Texas: *Research Assistant* August 2007 – July 2008
 Supervisor: Nicoladie Tam, PhD, Associate Professor, Biology

- Contributed to emotions model based on theoretical interpretations of neuroprocessing, in line with previous work from the Tam Lab
- Responsible for collection and basic analysis of retrospective research data
- Work was basis of Texas Academy of Math & Science Research Scholarship

Texas A&M University: *Research Assistant*

August 2009 – July 2010

Supervisor: Jennifer Bizon, PhD, Associate Professor, Department of Neuroscience

- Conducted various behavioral assays (including Morris water maze and transfer task) for comparative learning assessments and pharmacological experimentation in rodent model of Alzheimer's disease
- Responsible for experimental execution, data collection/analysis, and constructing academic poster
- Poster presented at Texas A&M Student Research Week and Texas A&M Neuroscience Symposium

Texas A&M University: *Honors Research Fellow*

August 2010 – July 2011

Supervisor: Danna Zimmer, PhD, Associate Professor, Veterinary Pathobiology

- Independent study in biochemistry of S100 protein family and mechanism of effect on Alzheimer's disease pathology
- Responsible for primary literature review, experimental design/execution, data collection/analysis, and writing of thesis as Honors Research Fellow
- First-author original research article published to Texas A&M OAKTrust Digital Repository; first-author poster presented at Texas A&M Student Research Week; Texas A&M Goldwater Scholarship Nominee

Baylor College of Medicine: *Research Collaboration*

May 2015 – May 2016

Supervisor: Nidal Moukaddam, MD, Assistant Professor, Psychiatry & Behavioral Sciences

- Analysis of substance abuse epidemiology and trends at Ben Taub General Hospital, a Harris County Level 1 Trauma Center
- Role included primary literature review, data analysis, and writing of manuscript
- First-author original research article published to The Bulletin of the Menninger Clinic; first-author poster presented at 2015 AAAP annual meeting

Baylor College of Medicine: *Independent Research*

June 2016 – May 2017

Supervisor: Thomas Kosten, MD, Professor, Psychiatry & Behavioral Sciences

- Investigated significance of "outcome expectancy" based framework in addressing synthetic cannabinoid use among adolescents
- Responsible for primary literature review and writing of manuscript
- First-author case report published to AJA; oral presentation at BCM Psychiatry Grand Rounds on November 9, 2016

Baylor College of Medicine: *Research Collaboration*

January 2016 – September 2019

Supervisor: Christopher Verrico, PhD, Assistant Professor, Psychiatry & Behavioral Sciences

- Investigating therapeutic potential of guanfacine in cannabis use disorder
- Responsible for primary literature review, data analysis, and manuscript writing
- First-author original research article published to JNCN; first-author poster presented at 2016 AAAP annual meeting as travel award recipient

Baylor College of Medicine: *Research Track Resident*

March 2019 – June 2021

Supervisor: Eric Storch, PhD, Professor, Psychiatry & Behavioral Sciences

- Investigated qualitative aspects of ketamine treatment in depression and attitudes toward psychiatric use of ketamine among various populations
- Responsible for primary literature review, experimental design/execution, data collection/analysis, and manuscript writing
- First-author original research articles published to JAD; first-author original research article published to JCAP

The Johns Hopkins University School of Medicine: *Postdoctoral Research Fellow*

July 2021 – June 2023

Supervisors: Roland Griffiths, PhD and Albert Garcia-Romeu, PhD

- Facilitated clinical trials and mixed-methods research involving psilocybin and ketamine/esketamine
- Roles included scientific collaborator, study physician, and session therapist for medication-assisted interventions
- Research articles published to JAD, Psychopharmacology, BJP, Frontiers; additional publications pending

Segal Trials: *Physician Sub-investigator*

September 2023 – January 2024

Supervisor: Rishi Kakar, MD

- Physician sub-investigator for Phase 1 – 3 schizophrenia and depression drug development trials at privately held inpatient research site based in Miami Lakes, Florida
- Role included performing study procedures and related duties in compliance with IRB-approved protocols

PUBLICATIONS

Original Research

1. **Mathai DS**, Zimmer DB. S100 inhibitors: A new paradigm for treating Alzheimer’s disease. *The OAKTrust Digital Repository*. Texas A&M University. Honors and Undergraduate Research. 2011. Available at: <http://oaktrust.library.tamu.edu/handle/1969.1/148785>.
 2. **Mathai DS**, Gordon M, Muchmore P, Matorin A, Shah A, Moukaddam N. Paradoxical increase in synthetic cannabinoid emergency-related presentations after city wide ban: Lessons from Houston, Texas. *The Bulletin of the Menninger Clinic*. 2016; 80(4):357–370.
 3. **Mathai DS**, Holst M, Rodgman C, Haile CN, Keller J, Hussain MZ, Kosten TR, Newton TF, Verrico CD. Guanfacine attenuates adverse effects of dronabinol (THC) on working memory in adolescent-onset heavy cannabis users: A pilot study. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 2017; 30(1):66-76
 4. Holst M*, **Mathai DS***, Patel MM, Rodgman C, Keller J, Hussain MZ, De La Garza R II, Kosten TR, Newton TF, Verrico CD. Use of guanfacine for cannabis use disorder and related symptomatology. *The American Journal on Addictions*. 2019; 28(6):455-464.
- *Shared first authorship
5. Verrico CD, **Mathai DS**, Gu H, Sampson AR, Lewis DA. Recovery from impaired working memory performance during chronic Δ -9-tetrahydrocannabinol administration to adolescent rhesus monkeys. *Journal of Psychopharmacology*. 2020; 34(2):211-222.
 6. **Mathai DS**, Meyer MJ, Storch EA, Kosten TR. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. *Journal of Affective Disorders*. 2020; 264:123-129.
 7. **Mathai DS**, McCathern AG, Guzik AG, Schneider SC, Weinzimmer SA, Cepeda SL, Garcia-Romeu A, Storch EA. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. *Journal of Child and Adolescent Psychopharmacology*. 2021;31(8):553-561.
 8. Barth AM, Meinert AC, Zopatti KL, **Mathai DS**, Leong AW, Dickinson EM, Goodman WK, Shah AA, Schneider SC, Storch EA. A qualitative inquiry of parents’ observations of their children’s mental health needs during the COVID-19 pandemic. *Children's Health Care*. 2021; 51(2):213-234.
 9. Guzik AG, Leong AW, Dickinson EM, Schneider SC, Zopatti K, Manis J, Meinert AC, Barth AM, Perez M, Campo DM, Weinzimmer SA, Cepeda SL, **Mathai DS**, Shah A, Goodman WK, Salloum A, Kennedy S, Ehrenreich-May J, Storch EA. Brief, parent-led, transdiagnostic cognitive-behavioral teletherapy for youth with emotional problems related to the COVID-19 pandemic. *Journal of Affective Disorders*. 2022; 301:130–137.
 10. **Mathai DS**, Lee SM, Mora V, O'Donnell KC, Garcia-Romeu A, Storch EA. Mapping consent practices for outpatient psychiatric use of ketamine. *Journal of Affective Disorders*. 2022; 312, 113–121.
 11. **Mathai DS**, Nayak SM, Yaden DB, Garcia-Romeu A. Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. *Psychopharmacology*. 2023; 240, 827–836.
 12. **Mathai DS**, Hilbert S, Sepeda ND, Strickland JC, Griffiths RR, Garcia-Romeu A. Double-blind comparison of the two hallucinogens dextromethorphan and psilocybin: Experience-dependent and enduring psychological effects in healthy volunteers. *Psychedelic Medicine*. 2023.
 13. Nayak SM, Jackson H, Sepeda ND, **Mathai DS**, So S, Yaffe A, Zaki H, Brasher TJ, Lowe MX, Jolly DR, Barrett FS, Griffiths RR, Strickland J, Johnson MW, Jackson H, Garcia-Romeu A. Naturalistic psilocybin use is associated with persisting improvements in mental health and well-being: Results from a prospective, longitudinal survey. *Frontiers in Psychiatry*. 2023.
 14. **Mathai DS**, Roberts DE, Nayak SM, Sepeda ND, Lehrner A, Johnson MW, Lowe MX, Jackson, H, Garcia-Romeu A. Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. *PsyArXiv Preprints*. 2023.
 15. Riddle DB, Guzik AG, Salloum A, Kennedy S, Shah A, Goodman WK, **Mathai DS**, Leong AW, Dickinson EM, Ayton DM, Weinzimmer SA, Ehrenreich-May J, Storch, EA. Predictors of treatment outcome for parent-led, transdiagnostic cognitive behavioral therapy for youth with emotional problems related to the COVID-19 pandemic. *Child & Youth Care Forum*. 2024.

Review Articles

1. **Mathai DS**. Borderline personality disorder and a spectrum of trauma. *Residents' Journal*. The American Journal of Psychiatry. 2015; 10(5):5–6.
2. **Mathai DS**. Persistent and long-term neuropsychiatric implications of cannabis use in adolescents. *Residents' Journal*. The American Journal of Psychiatry. 2017; 12(6):8–10.
3. McCathern AG, **Mathai DS**, Cho RY, Goodman WK, Storch, EA. Deep transcranial magnetic stimulation for obsessive compulsive disorder. *Expert Review of Neurotherapeutics*. 2020; 20(10): 1029–1036.
4. **Mathai DS**, Mora V, Garcia-Romeu A. Toward synergies of ketamine and psychotherapy. *Frontiers in Psychology*. 2022.

Case Reports & Letters

1. **Mathai DS**, Verrico CD, Shorter D, Coverdale JH, Kosten TR. “Just one bad high”: Considering synthetic cannabinoid outcome expectancies in adolescents. *The American Journal on Addictions*. 2016; 25(8):620–622.
2. **Mathai DS**, Yaden DB, O'Donnell KC. The conundrum of therapeutic intoxication. *The British Journal of Psychiatry*. 2022; 221(2):496–497.

Book Chapters

1. Vyas A, Vu-Sowers T, Billups D, **Mathai DS**, Saxena K. Childhood maltreatment and posttraumatic stress disorder. In: Giardino AP, ed. *Childhood Maltreatment: Emerging Issues in Practice, Care, and Prevention*. Nova Science Publishers; 2016; 85–104.
2. **Mathai DS**, Mathew SJ. Ketamine. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook of Psychopharmacology*. Fifth Edition. American Psychiatric Publishing; 2017.
3. **Mathai DS**, Mathew SJ. Ketamine and esketamine. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook of Psychopharmacology*. Sixth Edition. American Psychiatric Publishing; in press.
4. Yaden DB, **Mathai DS**, Bogenschutz MP, Nichols DE. The pharmacology of hallucinogens. In: Miller SC, Saitz R, eds. *Principles of Addiction Medicine*. Seventh Edition. American Society of Addiction Medicine; in press.

Other Media

1. **Mathai DS**. The cost of medical innovation [Internet]. Baylor College of Medicine: Progress Notes. October 2015. Available at: <https://blogs.bcm.edu/2015/10/26/the-cost-of-medical-innovation/>.
2. **Mathai DS**. Losing Darren [Internet]. Baylor College of Medicine: Progress Notes. December 2015. Available at: <https://blogs.bcm.edu/2015/12/14/losing-darren/>. Also published with permission to Texas MD Magazine.
3. **Mathai DS**. Deep brain stimulation and the era of scientific psychiatry [Internet]. Baylor College of Medicine: Progress Notes. April 2016. Available at: <https://blogs.bcm.edu/2016/04/18/deep-brain-stimulation-and-the-era-of-scientific-psychiatry/>.
4. **Mathai DS**, Mathew SJ, Storch EA, Kosten TR. Revisiting the hallucinogenic potential of ketamine [Internet]. *Psychiatric Times*. June 2018. Available at: <https://www.psychiatristimes.com/view/revisiting-hallucinogenic-potential-ketamine>.
5. Featured in Science Magazine article: Ketamine no better than placebo at alleviating depression, unusual trial finds. *Science*. May 2023. Available at: <https://www.science.org/content/article/ketamine-no-better-placebo-alleviating-depression-unusual-trial-finds>.
6. Featured on Tinny Matters podcast episode: What the (second) wave of psychedelics research could mean for mental health. American Chemical Society. May 2023. Available at: <https://www.acs.org/pressroom/tiny-matters/what-the-second-wave-of-psychedelics-research-could-mean-for-mental-health.html>.
7. Featured in interview with Psych Congress Network: Psychedelics: A Unique Psychiatric Paradigm. Psych Congress. June 2023. Available at: https://www.hmpgloballearningnetwork.com/site/pcn/qas/psychiatrics-unique-psychiatric-paradigm?hmpid=amFpbi50ZXhhc0BnbWFpbC5jb20=&utm_medium=email&utm_source=newsletter&utm_content=1821135091.
8. Featured on Mind Dive podcast episode: Psychedelic therapies for healing and recovery with Dr. David Mathai. The Menninger Clinic. November 2023. Available at: <https://www.buzzsprout.com/1924542/13986774>

ABSTRACTS & PRESENTATIONS

1. Montgomery KS, Edwards G, **Mathai DS**, Burton K, Setlow B, Bizon JL. Development of a novel, translational hippocampal-dependent learning assessment: Implications for early diagnosis of Alzheimer's Disease. Texas A&M Student

- Research Week; March 2010; College Station, Texas. Also presented at Texas A&M Neuroscience Symposium; April 2010; College Station, Texas.
2. **Mathai DS**, Zimmer DB. S100 Inhibitors: A new paradigm for treating Alzheimer's Disease. Texas A&M Student Research Week; March 2011; College Station, Texas.
 3. **Mathai DS**, Gordon M, Muchmore P, Matorin A, Shah A, Moukaddam N. Trends in synthetic cannabinoid use in Houston before and after citywide ban. American Academy of Addiction Psychiatry Annual Meeting; December 2015; Huntington Beach, California.
 4. **Mathai DS**, Holst M, Rodgman C, Haile CN, Keller J, Hussain MZ, Kosten TR, Newton TF, Verrico CD. Guanfacine affects dronabinol (THC)-induced cognitive effects in a human laboratory model. American Academy of Addiction Psychiatry Annual Meeting; December 2016; Bonita Springs, Florida.
 5. **Mathai DS**, Morain S, Verrico CD. Plant, endogenous, & synthetic cannabinoids: A brief medical & legal history. Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Sciences Grand Rounds; November 2016; Houston, Texas.
 6. **Mathai DS**, Verrico CD, Sampson AR, Lewis DA. The effects of repeated delta-9-tetrahydrocannabinol administration to adolescent rhesus monkeys on working memory. American Academy of Addiction Psychiatry Annual Meeting; December 2017; San Diego, California.
 7. **Mathai DS**, Mathew SJ, Storch EA, Kosten TR. Revisiting the hallucinogenic potential of ketamine: A case built on current research findings. American Psychiatric Association Research Colloquium for Junior Investigators; May 2018; New York, New York.
 8. **Mathai DS**, Prashad SJ. The relationship between ketamine-induced psychotomimetic and dissociative effects and treatment efficacy. American Society of Ketamine Physicians Annual Meeting; September 2018; Austin, Texas.
 9. **Mathai DS**. Ketamine in psychiatry: Do the hallucinogenic effects matter? Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Sciences Resident Research Symposium; May 2019; Houston, Texas.
 10. **Mathai DS**. The wounded healer: A reflection on trainee burn-out in psychiatry. Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Sciences Outcomes Review Conference; December 2019.
 11. **Mathai DS**. Learning which questions to ask: My journey to psychedelic science. Johns Hopkins Center for Psychedelic and Consciousness Research; October 2020; Baltimore, Maryland.
 12. **Mathai DS**, Bennett R. Making sense of the non-ordinary: Ketamine and emerging treatments that alter consciousness. Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Sciences Grand Rounds; October 2020; Houston, Texas.
 13. **Mathai DS**. Psychedelics in psychiatry. Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Science Medical Student Lecture; April 2021; Houston, Texas.
 14. **Mathai DS**. On the kaleidoscopic nature of reality. Stanford Department of Psychiatry and Behavioral Sciences Resident Psychedelic Conference; May 2021; Palo Alto, California.
 15. **Mathai DS**. What's in a treatment, anyway? Revisiting the extra-pharmacological processes that shape psychotropic drug response. Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Sciences Resident Research Symposium; June 2021; Houston, Texas.
 16. **Mathai DS**. Current directions and opportunities for psychedelic research. Baylor College of Medicine & Menninger Department of Psychiatry and Behavioral Sciences Resident Meeting; September 2021; Houston, Texas.
 17. Mora V, **Mathai DS**, Opekun AR, Storch EA. Informed consent for ketamine use in outpatient psychiatric practice: A systematic review of safety data. School of Health Professions J. David Holcomb Research Day; December 2021; Houston, Texas.
 18. Lee SM, **Mathai DS**, Mora V, Storch ES. Mapping consent practices for outpatient psychiatric use of ketamine. Harvard Medical School Psychiatry Research Day; March 2022; Boston, Massachusetts.
 19. **Mathai DS**. The confounding "Self:" How newly examined psychedelic treatments inform old psychiatric questions. Louisiana State University Baton Rouge Department of Psychiatry Grand Rounds; March 2022; Baton Rouge, Louisiana.
 20. **Mathai DS**. An overview of psychedelic therapy for substance use disorders. Maryland-DC Society of Addiction Medicine Spring Educational Conference; May 2022; Baltimore, Maryland.
 21. **Mathai DS**. Toward synergies of ketamine and psychotherapy. Ketamine International Journal Club; May 2022; Oxford, United Kingdom.
 22. Garcia-Romeu A, Wang E, Nayak SM, **Mathai DS**, Gukasyan N. Healthcare providers' knowledge and attitudes on cannabis-based treatment. International Cannabinoid Research Society Symposium on the Cannabinoids; June 2022; Galway, Ireland.
 23. **Mathai DS**. When consciousness divides: The converging stories of ketamine and dissociation. Stanford Psychedelic Science Group; July 2022; Palo Alto, California.

24. **Mathai DS**, Lee SM. A review of informed consent procedures for ketamine in psychiatry. *Ketamine International Journal Club*; July 2022; Oxford, United Kingdom.
25. **Mathai DS**. When consciousness divides: The converging stories of ketamine, dissociation, and psychedelic experience. *New York University Continuing Medical Education on Psychedelic Medicine*; October 2022; New York, New York.
26. **Mathai DS**. An overview of current psychedelic research. *Baltimore County Behavioral Health Advisory Council*; January 2023; Baltimore, Maryland.
27. **Mathai DS**. Expanding treatment options through psychedelics – What you need to know. *Psych Congress Elevate*; June 2023; Las Vegas, Nevada.
28. **Mathai DS**. L'influence somnambulique – Exploring dissociatives and dissociation within the psychedelic landscape. *Pitié-Salpêtrière hospital and the Paris Brain Institute*; June 2023; Paris, France.
29. Nayak SM, **Mathai DS**, Sepeda ND. Naturalistic psilocybin use is associated with persisting improvements in mental health and well-being in a large prospective sample. *Psychedelic Science 2023 with the Multidisciplinary Association of Psychedelic Studies*; June 2023; Denver, Colorado.
30. **Mathai DS**. The wrathful deities: Shame, guilt, and psychedelic experience. *Intercollegiate Psychedelics Network Seminar*; September 2023; North Miami, Florida.
31. **Mathai DS**. Shame, guilt, and psilocybin: On challenging inward journeys. *Psychedelic Safety Seminar with the International Psychedelic Safety Group*; September 2023; Virtual.
32. **Mathai DS**. When things fall apart: What the largest real-world study of psilocybin use can teach us about shame. *Wonderland Conference*; November 2023; Miami, Florida.

TEACHING EXPERIENCE

Chemistry Department, University of North Texas: *Organic Chemistry Teaching Assistant* January 2009 – May 2009

- Tutored university students for Dr. Sushama Dandekar as supplement to organic chemistry course

English Language Institute, Texas A&M University: *Classroom Partner* May 2010 – December 2012

- Worked with international university students to develop conversational English speaking skills

Biochemistry and Biophysics Department, Texas A&M University: *Department Tutor* August 2010 – December 2012

- Tutored university students in chemistry, microbiology, genetics, and biochemistry

Kaplan Test Prep, College Station and Waco, TX: *MCAT Instructor* August 2012 – July 2013

- Taught physics, biology, chemistry, and verbal reasoning for MCAT preparation course

Baylor College of Medicine Psychiatry Clerkship: *Lecturer* July 2018 – February 2021

- Responsible for recurrent didactic titled “Introduction to Psychotherapy” for medical students rotating on Psychiatry Clerkship
- Resident leader for “Finding Meaning in Psychiatry” reflection sessions built into clerkship curriculum

Baylor College of Medicine: *Clinical Supervision* July 2020 – June 2021

- Responsible for clinical supervision of masters-level therapists for “Coping with COVID” program, a collaboration between Baylor College of Medicine and the Harris Health System that provides free parent-led cognitive behavioral therapy (CBT) for children who are experiencing stress and anxiety related to the COVID-19 pandemic

Baylor College of Medicine/Johns Hopkins/University of Maryland School of Medicine: *Mentoring*

Kaitlyn Carlson (Baylor College of Medicine – Medical Student) May 2018 – December 2018

- Research supervisor for project on automated speech analysis in traumatic brain injury; project was not completed due to insufficient funding

Lily Buckner (Carnegie Vanguard – High School Student) October 2018 – October 2019

- Research supervisor for completed AP Research Project resulting in publication titled “The comparative efficacy of medication-based treatments for the treatment of opioid use disorder: A systematic review;” also completed letter of recommendation for this student’s college application

Matthew Meyer (Baylor College of Medicine – Medical Student) October 2018 – November 2019

- Research supervisor for completed project on dissociative effects of ketamine; resulted in peer-reviewed publication titled “The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review” (see #6 in Original Research)

Scott Lee (Baylor College of Medicine – Medical Student) June 2018 – July 2022

- Research supervisor for completed project on ethical aspects of informed consent for ketamine in psychiatry; resulted in poster (see #18 in Abstracts and Presentations) and publication (see #10 in Original Research) on psychiatric ketamine and informed consent

Alexis Moore-McCathern (Baylor College of Medicine – Medical Student) August 2019 – June 2021

- Research supervisor for completed project on transcranial magnetic stimulation for treatment of obsessive-compulsive disorder resulting in publication (see #3 in Review Articles) and completed project on parent attitudes toward ketamine in psychiatry resulting in publication (see #7 in Original Research)

Erin Wang (Johns Hopkins School of Medicine – Medical Student) August 2021 – present

- Research supervisor for active project examining healthcare professionals’ knowledge, attitudes, and concerns involving medical hallucinogens

Samantha Hilbert (Johns Hopkins – Research Program Coordinator) November 2021 – September 2023

- Research supervisor for project examining clinically relevant differences between dextromethorphan and psilocybin resulting in publication (see #12 in Original Research)

Tesiya Franklin (University of Maryland School of Medicine – Medical Student) July 2022 – present

- Research supervisor for active project examining recent epidemiology of hallucinogen use

Hadi Zaki (Johns Hopkins – Research Program Coordinator) September 2022 – present

- Research supervisor for active project developing a protocol for esketamine-assisted psychotherapy using Acceptance and Commitment Therapy (ACT)

ACTIVITIES & SERVICE

Baylor College of Medicine: *President of PsychMinded, Baylor’s Psychiatry Interest Group* January 2015 – May 2017

- Student Outreach: Assisted with annual mock interview panel for MS4 psychiatry applicants, Psychiatry Clerkship orientation for core medical students, psychiatry-themed film club, lunch lectures with Department faculty, publicizing psychiatry opportunities/awards
- Community Outreach: Contributed to Mental Health Curriculum at Houston middle schools (publicized, recruited instructors, taught "Drugs" lecture), community mental health fairs, NAMIWalks event

Baylor College of Medicine: *Medical Student Council, Director of Athletics* April 2016 – May 2017

- Coordinated intramural sports activities including annual football, basketball, volleyball, dodgeball, and softball leagues
- Advised administration about athletic facilities and needs (equipment, operating hours, etc.)

Baylor College of Medicine: *Editor of Progress Notes, Baylor’s Student Magazine* July 2016 – May 2017

- Served as editor for the Baylor student magazine through which students share stories from clinics, thoughts on medicine and healthcare, and updates in research
- Available at <https://progressnotes.bcm.edu/>

NeuroLex: *Innovation Fellow* October 2017 – November 2018

- Participated in Tribe 2 of Innovation Fellows Program
- Interned with seed-stage diagnostics company applying speech analysis and machine learning for health screening
- Collaborated with NeuroLex and researchers at Baylor College of Medicine to explore mental health applications of automated speech analysis

MEMBERSHIPS

- Society of Biological Psychiatry June 2016 – May 2018
- Attended Society of Biological Psychiatry annual meeting in 2016
- American Academy of Addiction Psychiatry December 2015 – May 2018
- Attended American Academy of Addiction Psychiatry annual meeting 2015-2017
 - Travel Award Recipient in 2016
 - Served as liaison/editor for 2017 Travel Awardees on behalf of The American Journal on Addictions
- American Group Psychotherapy Association January 2020 – June 2021
- Attended American Group Psychotherapy Association annual meeting 2020
 - Recipient of Robert & Sara Jane White Psychiatric Resident Scholarship

AWARDS & HONORS

2008	Texas Academy of Mathematics and Science Summer Research Scholarship; Denton TX
2009-2012	Directors Excellence Award; College Station TX
2010-2012	University Scholar; College Station TX
2010	Research Recognition Award; College Station TX
2010	Interdisciplinary Research Award; College Station TX
2011	College of Agriculture and Life Science Outstanding Student Award; College Station TX
2011	Goldwater Scholarship Nominee; College Station TX
2011-2012	Academic Excellence Award; College Station TX
2013	Voices Only 2013 album feature for collegiate a cappella track "Skyfall/Saans;" College Station TX
2015	Baylor College of Medicine Intramural Basketball Championship; Houston TX
2015	J.K. Alexander Travel Award; Houston TX
2016	Gold Humanism Honor Society Nominee; Houston TX
2016	The American Academy of Addiction Psychiatry Travel Award; Houston TX
2017	Hilde Bruch Award for Excellence in Psychiatry; Houston TX
2018	American Psychiatric Association Research Colloquium Junior Investigator Award; Houston TX
2019	Resident Research Symposium Certificate of Excellence; Houston TX
2020	Robert & Sara Jane White Psychiatric Resident Scholarship; Houston TX
2020	Stacia Micheletto Award in Psychodynamic Psychiatry; Houston TX